Home > Search Results: Shepherd, Frances A
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 3 records in 0.01 seconds.
Articles, 3 records found
Articles 3 records found  
1.
11 p, 379.4 KB Postoperative Chemotherapy Use and Outcomes From ADAURA : Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC / Wu, Yi-Long (Guangdong Lung Cancer Institute) ; John, Thomas (Austin Health) ; Grohe, Christian (Evangelische Lungenklinik) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Goldman, Jonathan W. (University of California) ; Kim, Sang-We (University of Ulsan) ; Kato, Terufumi (Kanagawa Cancer Center) ; Laktionov, Konstantin (Blokhin National Medical Research Center of Oncology) ; Vu, Huu Vinh (Choray Hospital) ; Wang, Zhije (Chinese Academy of Medical Sciences) ; Lu, Shun (Shanghai Jiao Tong University) ; Lee, Kye Young (Konkuk University Medical Center) ; Akewanlop, Charuwan (Siriraj Hospital) ; Yu, Chong-Jen (National Taiwan University College of Medicine) ; de Marinis, Filippo (European Institute of Oncology) ; Bonanno, Laura (Istituto Oncologico Veneto) ; Domine, Manuel (Instituto de Investigación Sanitaria-Fundación Jiménez Díaz) ; Shepherd, Frances A. (University of Toronto) ; Zeng, Lingmin (AstraZeneca) ; Atasoy, Ajlan (AstraZeneca) ; Herbst, Roy S. (Yale School of Medicine) ; Tsuboi, Masahiro (National Cancer Center Hospital East) ; Universitat Autònoma de Barcelona
Introduction: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful improvement in disease-free survival (DFS) in patients with resected stages IB to IIIA EGFR-mutated (EGFRm) NSCLC. [...]
2022 - 10.1016/j.jtho.2021.10.014
Journal of Thoracic Oncology, Vol. 17 Núm. 3 (march 2022) , p. 423-433  
Detailed record - Creative Commons
2.
11 p, 421.8 KB Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial / Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Goldman, Jonathan W. (David Geffen School of Medicine. University of California Los Angeles) ; John, Thomas (Department of Medical Oncology. Austin Health) ; Grohe, Christian (Klinik fur € Pneumologie-Evangelische Lungenklinik Berlin Buch) ; Laktionov, Konstantin (N.N. Blokhin National Medical Research Center of Oncology (Rússia)) ; Kim, Sang-We (Department of Oncology. Asan Medical Center) ; Kato, Terufumi (Depart-ment of Thoracic Oncology. Kanagawa Cancer Center) ; Vu, Huu Vinh (Department of Thoracic Surgery. Choray Hospital) ; Lu, Shun (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ; Li, Shanqing (Department of Thoracic Surgery. Peking Union Medical College Hospital. Chinese Academy of Medical Sciences) ; Lee, Kye Young (Pre-cision Medicine Lung Cancer Center. Konkuk University Medical Center) ; Akewanlop, Charuwan (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ; Yu, Chong-Jen (Department of Internal Medicine. National Taiwan University Hospital Hsinchu Branch. National Taiwan University College of Medicine) ; De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ; Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto (IOV). IRCCS) ; Domine, Manuel (Hospital Universitario Fundacion Jimenez Díaz. Servicio de Oncología) ; Shepherd, Frances A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Cancer Center. the University of Toronto) ; Atagi, Shinji (Department of Thoracic Oncology. National Hospital Organization Kinki-Chuo Chest Medical Center) ; Zeng, Lingmin (Late Oncology Statistics. AstraZeneca) ; Kulkarni, Dakshayini (Late Oncology R&D. AstraZeneca) ; Medic, Nenad (AstraZeneca Oncology Business Unit. Academy House) ; Tsuboi, Masahiro (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ; Herbst, Roy S. (Medical Oncology. Yale School of Medicine. Yale Cancer Center) ; Wu, Yi-Long (Guangdong Lung Cancer Institute)
Purpose: In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior adjuvant chemotherapy, resulted in a statistically significant and clinically meaningful disease-free survival benefit in completely resected stage IB-IIIA EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). [...]
2022 - 10.1158/1078-0432.CCR-21-3530
Clinical Cancer Research, Vol. 28 Núm. 11 (january 2022) , p. 2286-2296  
Detailed record - Creative Commons
3.
8 p, 455.0 KB Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer : a phase I/II randomized trial / Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Keedy, Vicki (Vanderbilt University Medical Center) ; Borghaei, Hossein (Fox Chase Cancer Center, Philadelphia) ; Shepherd, Frances A. (University of Toronto) ; Insa, Amelia (Hospital Clínic Universitari (València)) ; Brown, Holly (Merck & Co., Inc., Whitehouse Station) ; Fitzgerald, Timothy (Merck & Co., Inc., Whitehouse Station) ; Sathyanarayanan, Sriram (Whitehouse Station, NJ USA) ; Reilly, John F.. (Merck & Co., Inc., Whitehouse Station) ; Mauro, David (Merck & Co., Inc., Whitehouse Station) ; Hsu, Karl (Sanofi Aventis) ; Yan, Li (Merck & Co., Inc., Whitehouse Station) ; Universitat Autònoma de Barcelona
We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselected patients with refractory advanced non-small-cell lung cancer (NSCLC). [...]
2014 - 10.1186/2162-3619-3-26
Experimental Hematology & Oncology, Vol. 3 (november 2014)  
Detailed record - Creative Commons

See also: similar author names
1 Shepherd, F.A.
3 Shepherd, Frances A.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with